Back to Mentors

Sidney Taurel

Major Career Roles:

  • Chair and CEO, Eli Lilly & Co.
  • Board member and Chair of the Compensation Committee, IBM and Mc-Graw-Hill (now S&P Global)
  • Chair, Pearson plc

 

Other Career Highlights: 

  • Council member, President’s Homeland Security Advisory Council
  • Council member, President’s Export Council
  • Member, Advisory Committee for Trade Policy and Negotiations
  • Board member, ITT Inc.
  • Partner, Capital Royalty LP, now the CRG LP
  • Advisory Board member, Moelis & Co.
  • Advisory Board member, Almirall SA

 

 

 

Sidney Taurel has a vast wealth of international senior leadership experience with 20 years as Chair and CEO of FTSE 100, S&P 100, S&P 500, and private companies with multi-industry knowledge in education, finance, pharmaceuticals, publishing, and technology.

 

Sidney was previously Chair of Pearson plc, the world’s largest publishing and education company and a Board Member of HIG Acquisition Corporation. He is also Chair Emeritus at Eli Lilly & Co, and a member of the ATP (Association of Tennis Professionals) Audit and Finance Committee.

 

Sidney spent most of his career with the global pharmaceutical firm Eli Lilly & Co., a SPAC listed on the NYSE, where he served as CEO and Chair up to 2008, becoming Chair Emeritus in 2009.

 

During his time at Eli Lilly, Sidney also held three US Presidential appointments, serving firstly as a Council Member of the President’s Homeland Security Advisory Council, then on the President’s Export Council, and in 2007 becoming a member of the Advisory Committee for Trade Policy and Negotiations.

 

Sidney was also a member of the Boards of ITT Inc. where he chaired the Audit Committee and IBM Corp. where he chaired the Compensation Committee and of the McGraw-Hill companies (now S&P Global), where he chaired the Remuneration Committee.

 

He was also a Partner at Capital Royalty LP, now the CRG LP, and an Advisory Board Member at the global investment bank Moelis & Co., the Japanese company Takeda Pharmaceutical Co. Ltd and the Spanish pharmaceutical company Almirall SA.